Поиск предиктивных биомаркеров эффективности аллергенспецифической иммунотерапии на основе современных представлений о механизмах её действия
- Авторы: Тимошенко Д.О.1, Павлова К.С.1, Курбачева О.М.1,2
-
Учреждения:
- Государственный научный центр «Институт иммунологии»
- Московский государственный медико-стоматологический университет имени А.И. Евдокимова
- Выпуск: Том 20, № 2 (2023)
- Страницы: 187-200
- Раздел: Научные обзоры
- URL: https://journals.rcsi.science/raj/article/view/253521
- DOI: https://doi.org/10.36691/RJA7526
- ID: 253521
Цитировать
Аннотация
Аллергенспецифическая иммунотерапия является основным патогенетически обоснованным методом лечения аллергических заболеваний, действие которого не только приводит к уменьшению выраженности клинических симптомов, но и оказывает болезнь-модифицирующий эффект, препятствуя прогрессированию заболевания, развитию бронхиальной астмы и расширению спектра сенсибилизации.
Толерантность, формируемая в процессе аллергенспецифической иммунотерапии, опосредована сложным взаимодействием между различными клетками врождённого и адаптивного иммунитета. Несмотря на то, что к настоящему времени описаны основные механизмы действия аллергенспецифической иммунотерапии, с каждым годом представление об этих процессах становится всё более детализированным не только на клеточном, но и молекулярном и эпигенетическом уровнях. В свою очередь, глубокое понимание механизмов, лежащих в основе формирования и сохранения толерантности к аллергенам при проведении аллергенспецифической иммунотерапии, поможет в выявлении предиктивных биомаркеров эффективности, использование которых могло бы оптимизировать отбор пациентов для проведения аллергенспецифической иммунотерапии, предсказывая ответ пациента на терапию.
В настоящем обзоре изложены актуальные представления о механизмах действия аллергенспецифической иммунотерапии на различные звенья аллергического процесса; описаны предполагаемые предиктивные биомаркеры эффективности данного терапевтического метода с учётом перспективных направлений исследований в этой области.
Полный текст
Открыть статью на сайте журналаОб авторах
Дарья Олеговна Тимошенко
Государственный научный центр «Институт иммунологии»
Автор, ответственный за переписку.
Email: d.o.timoshenko@gmail.com
ORCID iD: 0000-0002-7585-1390
SPIN-код: 2714-0906
аспирант
Россия, 115522, Москва, Каширское шоссе, д. 24Ксения Сергеевна Павлова
Государственный научный центр «Институт иммунологии»
Email: ksenimedical@gmail.com
ORCID iD: 0000-0002-4164-4094
SPIN-код: 7593-0838
Scopus Author ID: 7004658159
ResearcherId: P-9255-2017
канд. мед. наук
Россия, 115522, Москва, Каширское шоссе, д. 24Оксана Михайловна Курбачева
Государственный научный центр «Институт иммунологии»; Московский государственный медико-стоматологический университет имени А.И. Евдокимова
Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694
SPIN-код: 5698-6436
д-р мед. наук, профессор
Россия, 115522, Москва, Каширское шоссе, д. 24; МоскваСписок литературы
- Федеральные клинические рекомендации по проведению аллергенспецифической иммунотерапии. Российская ассоциация аллергологов и клинических иммунологов, 2013. Режим доступа: https://raaci.ru/dat/pdf/7asit.pdf. Дата обращения: 15.02.2023.
- Muraro A., Roberts G. Translating knowledge into clinical practice Allergen Immunotherapy Guidelines Part 1: Systematic reviews. European Academy of Allergy and Clinical Immunology (EAACI), 2017. 192 р.
- Гущин И.С., Курбачева О.М. Аллергия и аллергенспецифическая иммунотерапия. Москва: Фармус Принт Медиа, 2010.
- Shamji M., Kappen J. H., Akdis M., et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: An EAACI Position Paper // Allergy. 2017. Vol. 72, N 8. P. 1156–1173. doi: 10.1111/ALL.13138
- Sözener Z.C., Mungan D., Cevhertas L. Tolerance mechanisms in allergen immunotherapy // Curr Opin Allergy Clin Immunol. 2020. Vol. 20, N 6. P. 591–601. doi: 10.1097/ACI.0000000000000693
- Kanagaratham C., Ansari Y., Lewis O., et al. IgE and IgG antibodies as regulators of mast cell and basophil functions in food allergy // Front Immunol. 2020. N 11. P. 603050. doi: 10.3389/fimmu.2020.603050
- Schmid J., Würtzen P., Siddhuraj P., et al. Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients // Allergy. 2021. Vol. 76, N 5. P. 1528–1538. doi: 10.1111/ALL.14264
- Eljaszewicz A., Ruchti F., Radzikowska U., et al. Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy // J Allergy Clin Immunol. 2021. Vol. 147, N 5. P. 1865–1877. doi: 10.1016/J.JACI.2020.08.042
- Wen H., Qu L., Zhang Y., et al. A dendritic cells-targeting nano-vaccine by coupling polylactic-co-glycolic acid-encapsulated allergen with mannan induces regulatory T cells // Int Arch Allergy Immunol. 2021. Vol. 182, N 9. P. 777–787. doi: 10.1159/000512872
- Sirvent S., Soria I., Cirauqui C., et al. Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1 // J Allergy Clin Immunol. 2016. Vol. 138, N 2. P. 558–567.e11. doi: 10.1016/J.JACI.2016.02.029
- Soria I., López-Relaño J., Viñuela M., et al. Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice // Allergy. 2018. Vol. 73, N 4. P. 875–884. doi: 10.1111/ALL.13396
- Benito-Villalvilla C., Pérez-Diego M., Angelina A., et al. Allergoid-mannan conjugates imprint tolerogenic features in human macrophages // Allergy. 2022. Vol. 77, N 1. P. 320–323. doi: 10.1016/J.JACI.2021.06.012
- Zimmer A., Bouley J., Le Mignon M., et al. A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy // J Allergy Clin Immunol. 2012. Vol. 129, N 4. P. 1020–1030. doi: 10.1016/J.JACI.2012.02.014
- Starchenka S., Heath M., Lineberry A., et al. Transcriptome analysis and safety profile of the early-phase clinical response to an adjuvanted grass allergoid immunotherapy // World Allergy Organ. 2019. Vol. 12, N 11. P. 100087. doi: 10.1016/J.WAOJOU.2019.100087
- López J., Imam M., Satitsuksanoa P., et al. Mechanisms and biomarkers of successful allergen-specific immunotherapy // Asia Pac Allergy. 2022. Vol. 12, N 4. P. e45. doi: 10.5415/apallergy.2022.12.e45
- Wambre E., Delong J., James E., et al. Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy // J Allergy Clin Immunol. 2012. Vol. 129, N 2. P. 544–551,551.e1-7. doi: 10.1016/J.JACI.2011.08.034
- Wambre E., Delong J., James E., et al. Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner // J Allergy Clin Immunol. 2014. Vol. 133, N 3. P. 872–879.e7. doi: 10.1016/J.JACI.2013.10.054
- Wambre E. Effect of allergen-specific immunotherapy on CD4+ T cells // Curr Opin Allergy Clin Immunol. 2015. Vol. 15, N 6. P. 581–587. doi: 10.1097/ACI.0000000000000216
- Dolch A., Kunz S., Dorn B., et al. IL-10 signaling in dendritic cells is required for tolerance induction in a murine model of allergic airway inflammation // Eur J Immunol. 2019. Vol. 49, N 2. P. 302–312. doi: 10.1002/EJI.201847883
- Scadding G., Calderon M., Shamji M., et al. Effect of 2 years of treatment with sublingual grass pollen immunotherapy on nasal response to allergen challenge at 3 years among patients with moderate to severe seasonal allergic rhinitis: The GRASS randomized clinical trial // JAMA. 2017. Vol. 317, N 6. P. 615–625. doi: 10.1001/JAMA.2016.21040
- Renand A., Shamji M., Harris K., et al. Synchronous immune alterations mirror clinical response during allergen immunotherapy // J Allergy Clin Immunol. 2018. Vol. 141, N 5. P. 1750-1760.e1. doi: 10.1016/J.JACI.2017.09.041
- Shamji M.H., Durham S.R. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers // J Allergy Clin Immunol. 2017. Vol. 140, N 6. P. 1485–1498. doi: 10.1016/j.jaci.2017.10.010
- Zemmour D., Zilionis R., Kiner E., et al. Single-cell gene expression reveals a landscape of regulatory T cell phenotypes shaped by the TCR // Nat Immunol. 2018. Vol. 19, N 3. P. 291–301. doi: 10.1038/S41590-018-0051-0
- Scadding G., Shamji M., Jacobson M., et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells // Clin Exp Allergy. 2010. Vol. 40, N 4. P. 598–606. doi: 10.1111/J.1365-2222.2010.03462.X
- Van de Veen W., Akdis M. Tolerance mechanisms of allergen immunotherapy // Allergy. 2020. Vol. 75, N 5. P. 1017–1018. doi: 10.1111/ALL.14126
- Boonpiyathad T., van de Veen W., Wirz O., et al. Role of Der p 1-specific B cells in immune tolerance during 2 years of house dust mite-specific immunotherapy // J Allergy Clin Immunol. 2019. Vol. 143, N 3. P. 1077–1086.e10. doi: 10.1016/J.JACI.2018.10.061
- Wang C.M., Chang C.B., Wu S.F. Differential DNA methylation in allergen-specific immunotherapy of asthma // Cell Mol Immunol. 2020. Vol. 17, N 9. P. 1017–1018. doi: 10.1038/s41423-020-0476-x
- Тимошенко Д.О., Кофиади И.А., Гудима Г.О., Курбачева О.М. Эпигенетика бронхиальной астмы // Иммунология. 2021. Т. 42. № 2. С. 93–101. doi: 10.33029/0206-4952-2021-42-2-93-101
- Swamy R., Reshamwala N., Hunter T., et al. Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy // J Allergy Clin Immunol. 2012. Vol. 130, N 1. P. 215–224.e7. doi: 10.1016/j.jaci.2012.04.021
- Syed A., Garcia M., Lyu S., et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3) // J Allergy Clin Immunol. 2014. Vol. 133, N 2. P. 500–510. doi: 10.1016/J.JACI.2013.12.1037
- Wang C., Chang C., Chan M., et al. Dust mite allergen-specific immunotherapy increases IL4 DNA methylation and induces Der p-specific T cell tolerance in children with allergic asthma // Cell Mol Immunol. 2018. Vol. 15, N 11. P. 963–972. doi: 10.1038/CMI.2017.26
- Shamji M., Layhadi J., Achkova D., et al. Role of IL-35 in sublingual allergen immunotherapy // J Allergy Clin Immunol. 2019. Vol. 143, N 3. P. 1131–1142.e4. doi: 10.1016/J.JACI.2018.06.041
- Rigas D., Lewis G., Aron J., et al. Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator-inducible T-cell costimulator ligand interaction // J Allergy Clin Immunol. 2017. Vol. 139, N 5. P. 1468–1477.e2. doi: 10.1016/J.JACI.2016.08.034
- Shamji M., Larson D., Eifan A., et al. Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy // J Allergy Clin Immunol. 2021. Vol. 148, N 4. P. 1061–1071.e11. doi: 10.1016/j.jaci.2021.03.030
- Shamji M., Valenta R., Jardetzky T., et al. The role of allergen-specific IgE, IgG and IgA in allergic disease // Allergy. 2021. Vol. 76, N 12. P. 3627–3641. doi: 10.1111/ALL.14908
- Van de Veen W., Akdis M. Role of IgG4 in IgE-mediated allergic responses // J Allergy Clin Immunol. 2016. Vol. 138, N 5. P. 1434–1435. doi: 10.1016/J.JACI.2016.07.022
- Orengo J., Radin A., Kamat V., et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement // Nat Commun. 2018. Vol. 9, N 1. P. 1421. doi: 10.1038/S41467-018-03636-8
- Kolfschoten M., Schuurman J., Losen M., et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange // Science. 2007. Vol. 317, N 5844. P. 1554–1557. doi: 10.1126/SCIENCE.1144603
- Heeringa J., McKenzie C., Varese N., et al. Induction of IgG2 and IgG4 B-cell memory following sublingual immunotherapy for ryegrass pollen allergy // Allergy. 2020. Vol. 75, N 5. P. 1121–1132. doi: 10.1111/ALL.14073
- Boonpiyathad T., Pradubpongsa P., Mitthamsiri W., et al. Allergen-specific immunotherapy boosts allergen-specific IgD production in house dust mite-sensitized asthmatic patients // Allergy. 2020. Vol. 75, N 6. P. 1457–1460. doi: 10.1111/ALL.14133
- Satitsuksanoa P., Daanje M., Akdis M., et al. Biology and dynamics of B cells in the context of IgE-mediated food allergy // Allergy. 2021. Vol. 76, N 6. P. 1707–1717. doi: 10.1111/ALL.14684
- Jansen K., Cevhertas L., Ma S., et al. Regulatory B cells, A to Z // Allergy. 2021. Vol. 76, N 9. P. 2699–2715. doi: 10.1111/ALL.14763
- Ma S., Satitsuksanoa P., Jansen K., et al. B regulatory cells in allergy // Immunol Rev. 2021. Vol. 299, N 1. P. 10–30. doi: 10.1111/IMR.12937
- Van de Veen W., Stanic B., Yaman G., et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses // J Allergy Clin Immunol. 2013. Vol. 131, N 4. P. 1204–1212. doi: 10.1016/J.JACI.2013.01.014
- Boonpiyathad T., Meyer N., Moniuszko M., et al. High-dose bee venom exposure induces similar tolerogenic B-cell responses in allergic patients and healthy beekeepers // Allergy. 2017. Vol. 72, N 3. P. 407–415. doi: 10.1111/ALL.12966
- Wang S., Xia P., Chen Y., et al. Regulatory innate lymphoid cells control innate intestinal inflammation // Cell. 2017. Vol. 171, N 1. P. 201–216.e18. doi: 10.1016/J.CELL.2017.07.027
- Morita H., Kubo T., Rückert B., et al. Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid // J Allergy Clin Immunol. 2019. Vol. 143, N 6. P. 2190–2201.e9. doi: 10.1016/J.JACI.2018.12.1018
- Golebski K., Layhadi J., Sahiner U., et al. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response // Immunity. 2021. Vol. 54, N 2. P. 291–307.e7. doi: 10.1016/J.IMMUNI.2020.12.013
- Федеральные клинические рекомендации по диагностике и лечению аллергического ринита. 2020. Режим доступа: https://cr.minzdrav.gov.ru/recomend/261_1. Дата обращения: 15.02.2023.
- Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы. 2021. Режим доступа: https://cr.minzdrav.gov.ru/recomend/359_2. Дата обращения: 15.02.2023.
- Shamji M.H., Ljørring C., Würtzen P.A. Predictive biomarkers of clinical efficacy of allergen-specific immunotherapy: How to proceed // Immunotherapy. 2013. Vol. 5, N 3. P. 203–206. doi: 10.2217/imt.13.6
- Muraro A., Roberts G. Translating knowledge into clinical practice Allergen Immunotherapy Guidelines Part 2: Systematic reviews. European Academy of Allergy and Clinical Immunology (EAACI), 2017. 190 р.
- Тимошенко Д.О., Павлова К.С., Курбачёва О.М., Ильина Н.И. Место молекулярной аллергодиагностики при проведении аллергенспецифической иммунотерапии // Российский аллергологический журнал. 2022. Т. 19, № 3. С. 336–345. doi: 10.36691/RJA1572
- Shamji M., Ljørring C., Francis J., et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy // Allergy. 2012. Vol. 67, N 2. P. 217–226. doi: 10.1111/J.1398-9995.2011.02745.X
- Dahl R., Kapp A., Colombo G., et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years // J Allergy Clin Immunol. 2008. Vol. 121, N 2. P. 512–518.e2. doi: 10.1016/J.JACI.2007.10.039
- Gleich G., Zimmermann E., Henderson L., et al. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: A six-year prospective study // J Allergy Clin Immunol. 1982. Vol. 70, N 4. P. 261–271. doi: 10.1016/0091-6749(82)90062-8
- Pilette C., Nouri-Aria K., Jacobson M., et al. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-β expression // J Immunol. 2007. Vol. 178, N 7. P. 4658–4666. doi: 10.4049/JIMMUNOL.178.7.4658
- Nouri-Aria K., Wachholz P., Francis J., et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity // J Immunol. 2004. Vol. 172, N 5. P. 3252–3259. doi: 10.4049/JIMMUNOL.172.5.3252
- Di Lorenzo G., Mansueto P., Pacor M., et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy // J Allergy Clin Immunol. 2009. Vol. 123, N 5. P. 1103–1110,1110.e1-4. doi: 10.1016/J.JACI.2009.02.012
- Fujimura T., Yonekura S., Horiguchi S., et al. Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis // Clini Immunol. 2011. Vol. 139, N 1. P. 65–74. doi: 10.1016/J.CLIM.2010.12.022
- Würtzen P., Lund G., Lund K., et al. A double-blind placebo-controlled birch allergy vaccination study II: Correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation // Clin Exp Allergy. 2008. Vol. 38, N 8. P. 1290–1301. doi: 10.1111/J.1365-2222.2008.03020.X
- Bohle B., Kinaciyan T., Gerstmayr M., et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation // J Allergy Clin Immunol. 2007. Vol. 120, N 3. P. 707–713. doi: 10.1016/J.JACI.2007.06.013
- Ciepiela O., Zawadzka-Krajewska A., Kotuła I., et al. Sublingual immunotherapy for asthma: Affects T-cells but does not impact basophil activation // Pediatric Allergy Immunol Pulmonol. 2014. Vol. 27, N 1. P. 17–23. doi: 10.1089/PED.2014.0328
- Schulten V., Tripple V., Seumois G., et al. Allergen-specific immunotherapy modulates the balance of circulating Tfh and Tfr cells // J Allergy Clin Immunol. 2018. Vol. 141, N 2. P. 775–777.e6. doi: 10.1016/j.jaci.2017.04.032
- Atkinson A., Colburn W., DeGruttola V., et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework // Clin Pharmacol Ther. 2001. Vol. 69, N 3. P. 89–95. doi: 10.1067/MCP.2001.113989
- Shamji M., Wilcock L., Wachholz P., et al. The IgE-facilitated allergen binding (FAB) assay: Validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses // J Immunol Methods. 2006. Vol. 317, N 1-2. P. 71–79. doi: 10.1016/J.JIM.2006.09.004
- Shamji M., Francis J., Würtzen P., et al. Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: Inhibition by blocking antibody responses after immunotherapy // J Allergy Clin Immunol. 2013. Vol. 132, N 4. P. 1003–1005.e1-4. doi: 10.1016/J.JACI.2013.05.025
- Liu J., Hu M., Tao X., et al. Salivary IgG4 levels contribute to assessing the efficacy of dermatophagoides pteronyssinus subcutaneous immunotherapy in children with asthma or allergic rhinitis // J Clin Med. 2023. Vol. 12, N 4. P. 1665. doi: 10.3390/JCM12041665
- Knol E., Mul F., Jansen H., et al. Monitoring human basophil activation via CD63 monoclonal antibody 435 // J Allergy Clin Immunol. 1991. Vol. 88, N 3. P. 328–338. doi: 10.1016/0091-6749(91)90094-5
- Ebo D., Bridts C., Mertens C., et al. Analyzing histamine release by flow cytometry (HistaFlow): A novel instrument to study the degranulation patterns of basophils // J Immunol Methods. 2012. Vol. 375, N 1-2. P. 30–38. doi: 10.1016/j.jim.2011.09.003
- Nullens S., Sabato V., Faber M., et al. Basophilic histamine content and release during venom immunotherapy: Insights by flow cytometry // Cytometry B Clin Cytom. 2013. Vol. 84B, N 3. P. 173–178. doi: 10.1002/CYTO.B.21084
- Jutel M., Akdis M., Budak F., et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy // Eur J Immunol. 2003. Vol. 33, N 5. P. 1205–1214. doi: 10.1002/EJI.200322919
- Faith A., Richards D., Verhoef A., et al. Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and jun B: Relevance to immunotherapy // Clin Exp Allergy. 2003. Vol. 33, N 9. P. 1209–1215. doi: 10.1046/J.1365-2222.2003.01748.X
- Ebner C., Siemann U., Bohle B., et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen // Clin Exp Allergy. 1997. Vol. 27, N 9. P. 1007–1015. doi: 10.1111/J.1365-2222.1997.TB01252.X
- Fanta C., Bohle B., Hirt W., et al. Systemic immunological changes induced by administration of grass pollen allergens via the oral mucosa during sublingual immunotherapy // Int Arch Allergy Immunol. 1999. Vol. 120, N 3. P. 218–224. doi: 10.1159/000024270
- Cosmi L., Santarlasci V., Angeli R., et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production // Clin Exp Allergy. 2006. Vol. 36, N 3. P. 261–272. doi: 10.1111/J.1365-2222.2006.02429.X
- Wachholz P., Nouri-Aria K., Wilson D., et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios // Immunology. 2002. Vol. 105, N 1. P. 56–62. doi: 10.1046/J.1365-2567.2002.01338.X
- Francis J.N., Till S.J., Durham S.R. Induction of IL-10+CD4+CD25+T cells by grass pollen immunotherapy // J Allergy Clin Immunol. 2003. Vol. 111, N 6. P. 1255–1261. doi: 10.1067/mai.2003.1570
- Plewako H., Holmberg K., Oancea I., et al. A follow-up study of immunotherapy-treated birch-allergic patients: effect on the expression of chemokines in the nasal mucosa // Clin Exp Allergy. 2008. Vol. 38, N 7. P. 1124–1131. doi: 10.1111/J.1365-2222.2008.03005.X
- Makino Y., Noguchi E., Takahashi N., et al. Apolipoprotein A-IV is a candidate target molecule for the treatment of seasonal allergic rhinitis // J Allergy Clin Immunol. 2010. Vol. 126, N 6. P. 1163–1169.e5. doi: 10.1016/J.JACI.2010.06.031
- Li H., Xu E., He M. Cytokine responses to specific immunotherapy in house dust mite-induced allergic rhinitis patients // Inflammation. 2015. Vol. 38, N 6. P. 2216–2223. doi: 10.1007/S10753-015-0204-3
- Sakashita M., Yamada T., Imoto Y., et al. Long-term sublingual immunotherapy for Japanese cedar pollinosis and the levels of IL-17A and complement components 3a and 5a // Cytokine. 2015. Vol. 75, N 1. P. 181–185. doi: 10.1016/J.CYTO.2015.03.019
- Scadding G., Eifan A., Lao-Araya M., et al. Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge // Allergy. 2015. Vol. 70, N 6. P. 689–696. doi: 10.1111/ALL.12608
- Ciprandi G., De Amici M., Murdaca G., et al. Adipokines and sublingual immunotherapy: Preliminary report // Hum Immunol. 2009. Vol. 70, N 1. P. 73–78. doi: 10.1016/J.HUMIMM.2008.10.001
- Kirmaz C., Kirgiz O., Bayrak P., et al. Effects of allergen-specific immunotherapy on functions of helper and regulatory T cells in patients with seasonal allergic rhinitis // Eur Cytokine Netw. 2011. Vol. 22, N 1. P. 15–23. doi: 10.1684/ECN.2011.0277
- Xie S., Jiang S., Zhang H., et al. Prediction of sublingual immunotherapy efficacy in allergic rhinitis by serum metabolomics analysis // Int Immunopharmacol. 2021. N 90. P. 107211. doi: 10.1016/J.INTIMP.2020.107211
- Zheng P., Yan G., Zhang Y., et al. Metabolomics reveals process of allergic rhinitis patients with single- and double-species mite subcutaneous immunotherapy // Metabolites. 2021. Vol. 11, N 9. P. 613. doi: 10.3390/METABO11090613
- Shamji M., Layhadi J., Perera-web A., et al. IL-35+ Regulatory T Cells suppress grass pollen-driven Th2 responses and are induced following grass pollen-specific sublingual immunotherapy // J Allergy Clin Immunol. 2013. Vol. 131, N 2. P. AB146. doi: 10.1016/j.jaci.2012.12.1182
- Gueguen C., Bouley J., Moussu H., et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy // J Allergy Clin Immunol. 2016. Vol. 137, N 2. P. 545–558. doi: 10.1016/j.jaci.2015.09.015
- O’Mahony L., Akdis C.A., Eiwegger T. Innate mechanisms can predict successful allergy immunotherapy // J Allergy Clin Immunol. 2016. Vol. 137, N 2. P. 559–561. doi: 10.1016/J.JACI.2015.10.047
- Wang C., Chang C., Lee S., et al. Differential DNA methylation profiles of peripheral blood mononuclear cells in allergic asthmatic children following dust mite immunotherapy // J Microbiol Immunol Inf. 2020. Vol. 53, N 6. P. 986–995. doi: 10.1016/j.jmii.2020.06.004
- Jakwerth C., Chaker A., Guerth F., et al. Sputum microRNA-screening reveals Prostaglandin EP3 receptor as selective target in allergen-specific immunotherapy // Clin Exp Allergy. 2021. Vol. 51, N 12. P. 1577–1591. doi: 10.1111/CEA.14013